Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
44.12
-1.59 (-3.48%)
At close: Jun 27, 2025, 4:00 PM
44.09
-0.03 (-0.07%)
After-hours: Jun 27, 2025, 7:24 PM EDT
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $22.10M in the quarter ending March 31, 2025, with 114.83% growth. This brings the company's revenue in the last twelve months to $58.89M, down -25.85% year-over-year. In the year 2024, Kymera Therapeutics had annual revenue of $47.07M, down -40.11%.
Revenue (ttm)
$58.89M
Revenue Growth
-25.85%
P/S Ratio
61.03
Revenue / Employee
$313,218
Employees
188
Market Cap
2.87B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
KYMR News
- 1 day ago - Kymera Therapeutics Announces Pricing of $250 Million Public Offering - GlobeNewsWire
- 2 days ago - Kymera Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 3 days ago - Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics - Reuters
- 3 days ago - Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update - GlobeNewsWire
- 3 days ago - Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders - Business Wire
- 22 days ago - Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial - Barrons
- 25 days ago - Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data - Seeking Alpha
- 26 days ago - Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster. - Barrons